Literature DB >> 19099197

Contributions of biological tumor parameters to the incorporation rate of L: -[methyl-(11)C] methionine into astrocytomas and oligodendrogliomas.

Takeko Nojiri1, Tadashi Nariai, Masaru Aoyagi, Michio Senda, Kenji Ishii, Kiichi Ishiwata, Kikuo Ohno.   

Abstract

We compared the tumor uptake of (11)C-methionine (MET) with positron emission tomography (PET) with the results of a pathological analysis to examine the proliferative potential and microvessel density measured with immunostaining for MIB-1 and factor VIII, respectively, from 33 patients with glioma. The MET uptake in oligodendrogliomas was significantly greater than that in grade 2 astrocytomas and comparable to those in grade 3 and 4 astrocytomas. The MIB-1 index of oligodendroglioma meanwhile was comparable to that of grade 2 astrocytoma. The microvessel area in oligodendroglioma was significantly greater than that in grade 2 astrocytomas and comparable to those in grade 3 and 4 astrocytomas. According to a multivariate statistical analysis, MET uptake ratio was closely correlated with the MIB-1 index among astrocytomas. An increase in the microvessel area in the oligodendrogliomas contributed to the higher MET uptake among the tumors with a low-proliferative index. This information is important for interpreting the results of MET-PET studies for clinical use.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19099197     DOI: 10.1007/s11060-008-9767-2

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  42 in total

1.  Positron emission tomography (11)C-methionine and survival in patients with low-grade gliomas.

Authors:  D Ribom; A Eriksson; M Hartman; H Engler; A Nilsson; B Långström; H Bolander; M Bergström; A Smits
Journal:  Cancer       Date:  2001-09-15       Impact factor: 6.860

2.  Usefulness of 11C-methionine PET in the evaluation of brain lesions that are hypo- or isometabolic on 18F-FDG PET.

Authors:  June-Key Chung; Yu Kyeong Kim; Seok-ki Kim; Yong Jin Lee; Suntta Paek; Jeong Seok Yeo; Jae Min Jeong; Dong Soo Lee; Hee Won Jung; Myung Chul Lee
Journal:  Eur J Nucl Med Mol Imaging       Date:  2002-02       Impact factor: 9.236

3.  Delineation of brain tumor extent with [11C]L-methionine positron emission tomography: local comparison with stereotactic histopathology.

Authors:  Lutz W Kracht; Hrvoje Miletic; Susanne Busch; Andreas H Jacobs; Jurgen Voges; Moritz Hoevels; Johannes C Klein; Karl Herholz; Wolf-D Heiss
Journal:  Clin Cancer Res       Date:  2004-11-01       Impact factor: 12.531

4.  Immunohistochemical detection of progesterone receptors and the correlation with Ki-67 labeling indices in paraffin-embedded sections of meningiomas.

Authors:  G Nagashima; M Aoyagi; H Wakimoto; M Tamaki; K Ohno; K Hirakawa
Journal:  Neurosurgery       Date:  1995-09       Impact factor: 4.654

5.  Computerized tomographic and pathologic studies of the untreated, quiescent, and recurrent glioblastoma multiforme.

Authors:  P C Burger; P J Dubois; S C Schold; K R Smith; G L Odom; D C Crafts; F Giangaspero
Journal:  J Neurosurg       Date:  1983-02       Impact factor: 5.115

6.  Correlation of MR imaging-determined cerebral blood volume maps with histologic and angiographic determination of vascularity of gliomas.

Authors:  T Sugahara; Y Korogi; M Kochi; I Ikushima; T Hirai; T Okuda; Y Shigematsu; L Liang; Y Ge; Y Ushio; M Takahashi
Journal:  AJR Am J Roentgenol       Date:  1998-12       Impact factor: 3.959

7.  Kinetics of neutral amino acid transport across the blood-brain barrier.

Authors:  Q R Smith; S Momma; M Aoyagi; S I Rapoport
Journal:  J Neurochem       Date:  1987-11       Impact factor: 5.372

8.  Comparison of the accumulation kinetics of L-(methyl-11C)-methionine and D-(methyl-11C)-methionine in brain tumors studied with positron emission tomography.

Authors:  M Bergström; H Lundqvist; K Ericson; A Lilja; P Johnström; B Långström; H von Holst; L Eriksson; G Blomqvist
Journal:  Acta Radiol       Date:  1987 May-Jun       Impact factor: 1.990

9.  11C-methionine PET as a prognostic marker in patients with glioma: comparison with 18F-FDG PET.

Authors:  Sungeun Kim; June-Key Chung; So-Hyang Im; Jae Min Jeong; Dong Soo Lee; Dong Gyu Kim; Hee Won Jung; Myung Chul Lee
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-08-10       Impact factor: 9.236

10.  Relatively decreased 11C-methionine uptake within the anaplastic component of a mixed-grade oligodendroglioma.

Authors:  K Miwa; J Shinoda; H Yano; T Iwama
Journal:  AJNR Am J Neuroradiol       Date:  2007-09-28       Impact factor: 3.825

View more
  15 in total

1.  Independent prognostic value of pre-treatment 18-FDG-PET in high-grade gliomas.

Authors:  Cécile Colavolpe; Philippe Metellus; Julien Mancini; Maryline Barrie; Céline Béquet-Boucard; Dominique Figarella-Branger; Olivier Mundler; Olivier Chinot; Eric Guedj
Journal:  J Neurooncol       Date:  2011-12-15       Impact factor: 4.130

2.  MRI-suspected low-grade glioma: is there a need to perform dynamic FET PET?

Authors:  Nathalie L Jansen; Vera Graute; Lena Armbruster; Bogdana Suchorska; Juergen Lutz; Sabina Eigenbrod; Paul Cumming; Peter Bartenstein; Jörg-Christian Tonn; Friedrich Wilhelm Kreth; Christian la Fougère
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-04-11       Impact factor: 9.236

3.  Oligodendroglial component complicates the prediction of tumour grading with metabolic imaging.

Authors:  Osamu Manabe; Naoya Hattori; Shigeru Yamaguchi; Kenji Hirata; Kentaro Kobayashi; Shunsuke Terasaka; Hiroyuki Kobayashi; Hiroaki Motegi; Tohru Shiga; Keiichi Magota; Noriko Oyama-Manabe; Ken-ichi Nishijima; Yuji Kuge; Nagara Tamaki
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-02-03       Impact factor: 9.236

4.  Detection of histological anaplasia in gliomas with oligodendroglial components using positron emission tomography with (18)F-FDG and (11)C-methionine: report of two cases.

Authors:  Shigeru Yamaguchi; Hiroyuki Kobayashi; Kenji Hirata; Tohru Shiga; Shinya Tanaka; Junichi Murata; Shunsuke Terasaka
Journal:  J Neurooncol       Date:  2010-06-15       Impact factor: 4.130

5.  11C-methionine uptake correlates with combined 1p and 19q loss of heterozygosity in oligodendroglial tumors.

Authors:  T Saito; T Maruyama; Y Muragaki; M Tanaka; M Nitta; J Shinoda; T Aki; H Iseki; K Kurisu; Y Okada
Journal:  AJNR Am J Neuroradiol       Date:  2012-07-05       Impact factor: 3.825

6.  Evaluation of brain tumors using dynamic 11C-methionine-PET.

Authors:  Tatsuki Aki; Noriyuki Nakayama; Shingo Yonezawa; Syunsuke Takenaka; Kazuhiro Miwa; Yoshitaka Asano; Jun Shinoda; Hirohito Yano; Toru Iwama
Journal:  J Neurooncol       Date:  2012-04-22       Impact factor: 4.130

7.  Prediction of oligodendroglial histology and LOH 1p/19q using dynamic [(18)F]FET-PET imaging in intracranial WHO grade II and III gliomas.

Authors:  Nathalie L Jansen; Christoph Schwartz; Vera Graute; Sabina Eigenbrod; Jürgen Lutz; Rupert Egensperger; Gabriele Pöpperl; Hans A Kretzschmar; Paul Cumming; Peter Bartenstein; Jörg-Christian Tonn; Friedrich-Wilhelm Kreth; Christian la Fougère; Niklas Thon
Journal:  Neuro Oncol       Date:  2012-10-22       Impact factor: 12.300

8.  Correlation between positron emission tomography findings and glucose transporter 1, 3 and L-type amino acid transporter 1 mRNA expression in primary central nervous system lymphomas.

Authors:  Yoshinobu Takahashi; Toshiaki Akahane; Daisuke Yamamoto; Hideo Nakamura; Hiroki Sawa; Kazumi Nitta; Wataru Ide; Ikuo Hashimoto; Hajime Kamada
Journal:  Mol Clin Oncol       Date:  2014-05-05

9.  Clinical impact of (11)C-methionine PET on expected management of patients with brain neoplasm.

Authors:  Tomohiko Yamane; Setsu Sakamoto; Michio Senda
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-11-14       Impact factor: 9.236

Review 10.  Usefulness of FMISO-PET for glioma analysis.

Authors:  Hiroyuki Kobayashi; Kenji Hirata; Shigeru Yamaguchi; Shunsuke Terasaka; Tohru Shiga; Kiyohiro Houkin
Journal:  Neurol Med Chir (Tokyo)       Date:  2013-10-29       Impact factor: 1.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.